GlassScriptPhysician profile
Ramsha Haider
NPI 1962956417
$1,280.17
in general payments reported to CMS, 2019-2025
21 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.60 · 2020: $62.73 · 2021: $175 · 2022: $422 · 2023: $95.86 · 2024: $52.75 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $207.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.95 | 2021-2023 | Glassia |
| Glaxosmithkline, LLC. | $128.45 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $115.06 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $113.86 | 2020-2025 | Tezspire, Airsupra |
| Lilly USA, LLC | $84.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $79.08 | 2025 | |
| Philips North America LLC | $59.37 | 2022 | |
| Amgen INC. | $46.36 | 2024-2025 | Repatha, Otezla, Otezla |
| Nalu Medical, INC. | $43.85 | 2025 | Nalu Neurostimulation System |
| Exact Sciences Corporation | $37.89 | 2023-2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $35.67 | 2021 | |
| Medtronic, INC. | $31.08 | 2023-2025 | Intellis Adaptivestim, Venaseal |
| Currax Pharmaceuticals LLC | $28.24 | 2025 | Contrave, Onzetra Xsail |
| Ani Pharmaceuticals, INC. | $24.25 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $23.43 | 2022 | |
| Fisher & Paykel Healthcare INC | $19.66 | 2021 | |
| Viatris Specialty LLC | $17.05 | 2025 | Yupelri |
| Pfizer INC. | $15.17 | 2024 | |
| Merck Sharp & Dohme LLC | $14.38 | 2021 | |
| Mylan Specialty L.P. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsha Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.